Retrospective Study
Copyright ©The Author(s) 2023.
World J Clin Oncol. Nov 24, 2023; 14(11): 459-470
Published online Nov 24, 2023. doi: 10.5306/wjco.v14.i11.459
Table 2 Comparison of the clinical features of the surgical safety group and liver dysfunction group (mean ± SD)
VariablesTotalPostoperative liver function
P value
No liver dysfunction
Liver dysfunction
Sex
Male191271.000
Female16115
Age (yr)
< 60201460.721
≥ 601596
BMI
< 24 kg/m2211380.721
> 24 kg/m214104
BSA (m2)1.71 ± 0.181.75 ± 0.160.514
WBC (× 109/L)5.51 ± 2.395.19 ± 1.550.672
RBC (1012/L)4.30 ± 0.654.61 ± 0.440.146
PLT (× 109/L)126.17 ± 53.74149.33 ± 79.830.314
ALB (g/L)40.71 ± 4.2339.63 ± 4.180.478
Scr (μmol/L)76.98 ± 39.0764.87 ± 10.630.303
ALT [U/L, M (QR)]67.26 ± 94.4146.58 ± 30.400.468
AST [U/L, M (QR)]45.61 ± 23.6358.00 ± 68.680.436
TB [umol/L, M (QR)]15.63 ± 7.2020.99 ± 8.360.056
GGT [U/L, M (QR)]115.17 ± 112.78124.00 ± 145.780.844
AFP [ng/mL, M (QR)]9999.23 ± 25773.408545.66 ± 15372.770.859
PIVKA-II [μg/L, M (QR)]1799.54 ± 5017.783574.73 ± 6543.790.378
PT (s)12.59 ± 1.4612.39 ± 1.040.682
INR (s)1.10 ± 0.121.05 ± 0.110.227
LSM value (kPa)20.34 ± 4.8925.78 ± 5.380.005a
ICG R15 (%)7.99 ± 5.1311.96 ± 6.430.055
SRLV (L/m2)0.349 ± 0.0750.276 ± 0.0360.003a
Tumor-localizing
Left half liver151051.000
Right half liver20137
Tumor diameter [cm, M (QR)]6.63 ± 3.867.81 ± 4.910.436
Time of hepatic portal occlusion [min, M (QR)]14.65 ± 19.4215.75 ± 14.100.864
Intraoperative bleeding [mL, M (QR)]908.70 ± 818.761541.67 ± 1612.570.130
Operation time (min)176.30 ± 49.98185.83 ± 72.890.651